Trial

NCT02431260

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
Condition
Solid Tumors and Hematologic Malignancy
Intervention
INCB054329 Monotherapy
Why stopped
As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-14